View Financial HealthDiagnosTear Technologies 配当と自社株買い配当金 基準チェック /06DiagnosTear Technologies配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • 8hNew major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.8m (US$9.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (CA$13.8m market cap, or US$9.93m).お知らせ • Jul 10Diagnostear Technologies Inc. Reports Interim Clinical Study Results Demonstrating Excellent Correlation Between Tearx Red Eye and Quantitative Elisa TestingDiagnosTear Technologies Inc. announced positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026. Interim results were obtained and analyzed from 30 tear samples originating from the first 10 subjects tested before and after ocular provocation with feline allergen. Each tear sample was tested using both the TeaRx Red Eye product developed by the Company and a quantitative reference Enzyme Immunoassay (ELISA) for human Immunoglobulin E (IgE). The results indicated excellent concordance between the two methods, with a correlation coefficient (R2) greater than 0.95. TeaRx Red Eye is being developed as a rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis at the point of care. The Company expects to continue advancing the study with AlyaTec and will provide further updates as additional results become available.New Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m).お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canadaお知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering.お知らせ • Jun 04DiagnosTear Technologies Inc. announced that it expects to receive CAD 0.7 million in fundingDiagnosTear Technologies Inc. announced a non-brokered private placement of 1,400,000 units at a price of CAD 0.5 per unit for the gross proceeds of CAD 700,000 on June 3, 2025. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of CAD 1.00 for a term of eighteen months from the closing date of the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof.New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (CA$13.5m market cap, or US$9.77m).お知らせ • Feb 17DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025.決済の安定と成長配当データの取得安定した配当: DTRの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DTRの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場DiagnosTear Technologies 配当利回り対市場DTR 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DTR)n/a市場下位25% (CA)1.6%市場トップ25% (CA)5.5%業界平均 (Medical Equipment)1.9%アナリスト予想 (DTR) (最長3年)n/a注目すべき配当: DTRは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DTRは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DTRの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DTRが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/07 04:26終値2026/08/07 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DiagnosTear Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • 8hNew major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.8m (US$9.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (CA$13.8m market cap, or US$9.93m).
お知らせ • Jul 10Diagnostear Technologies Inc. Reports Interim Clinical Study Results Demonstrating Excellent Correlation Between Tearx Red Eye and Quantitative Elisa TestingDiagnosTear Technologies Inc. announced positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026. Interim results were obtained and analyzed from 30 tear samples originating from the first 10 subjects tested before and after ocular provocation with feline allergen. Each tear sample was tested using both the TeaRx Red Eye product developed by the Company and a quantitative reference Enzyme Immunoassay (ELISA) for human Immunoglobulin E (IgE). The results indicated excellent concordance between the two methods, with a correlation coefficient (R2) greater than 0.95. TeaRx Red Eye is being developed as a rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis at the point of care. The Company expects to continue advancing the study with AlyaTec and will provide further updates as additional results become available.
New Risk • Apr 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$19.6m market cap, or US$14.3m).
お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canada
お知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.
お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering.
お知らせ • Jun 04DiagnosTear Technologies Inc. announced that it expects to receive CAD 0.7 million in fundingDiagnosTear Technologies Inc. announced a non-brokered private placement of 1,400,000 units at a price of CAD 0.5 per unit for the gross proceeds of CAD 700,000 on June 3, 2025. Each unit will consist of one common share of the company and one common share purchase warrant. Each warrant will be exercisable to purchase one common share at an exercise price of CAD 1.00 for a term of eighteen months from the closing date of the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the issuance thereof.
New Risk • Apr 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (CA$13.5m market cap, or US$9.77m).
お知らせ • Feb 17DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025DiagnosTear Technologies Inc., Annual General Meeting, Apr 24, 2025.